Logo

Bionano Genomics: Hannah Mamuszka, Yvonne Linney, Junfeng Wang

May 04, 2020

Bionano Genomics has added Hannah Mamuszka and Yvonne Linney to its board of directors. Junfeng Wang, who joined the board as a representative of Legend Capital, has resigned from the board.

Mamuszka is the founder and CEO of Alva 10, an advisor on reimbursement for diagnostic testing. Prior to that, she was VP of Business Development and Clinical Strategy at Exosome Diagnostics. She has also held leadership positions at Asuragen, Oncotech, and Millennium Pharmaceuticals. She holds a master's degree in molecular biology from Harvard University.

Yvonne Linney is the founder of Linney BioConsulting. She has also served as CEO of Transcriptic, now operating as Strateos, where she was also COO and served on the board, and served in executive positions at Agilent Technologies, Bayer Diagnostics, and Caliper Life Sciences. She holds a doctorate in genetics from Leicester University in the UK.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.